0001209191-23-018571.txt : 20230314
0001209191-23-018571.hdr.sgml : 20230314
20230314175019
ACCESSION NUMBER: 0001209191-23-018571
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230314
FILED AS OF DATE: 20230314
DATE AS OF CHANGE: 20230314
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Prasad Raju
CENTRAL INDEX KEY: 0001968317
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37923
FILM NUMBER: 23732310
MAIL ADDRESS:
STREET 1: CRISPR THERAPEUTICS, INC.
STREET 2: 105 W FIRST STREET
CITY: BOSTON
STATE: MA
ZIP: 02127
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CRISPR Therapeutics AG
CENTRAL INDEX KEY: 0001674416
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 473173478
STATE OF INCORPORATION: V8
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: BAARERSTRASSE 14
CITY: ZUG
STATE: V8
ZIP: CH-6300
BUSINESS PHONE: 6173154600
MAIL ADDRESS:
STREET 1: BAARERSTRASSE 14
CITY: ZUG
STATE: V8
ZIP: CH-6300
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2023-03-14
0
0001674416
CRISPR Therapeutics AG
CRSP
0001968317
Prasad Raju
C/O CRISPR THERAPEUTICS, INC.
105 WEST FIRST STREET
BOSTON
MA
02127
0
1
0
0
Chief Financial Officer
Restricted Stock Units
2023-03-14
4
A
0
40000
0.00
A
Common Shares
40000
40000
D
Stock Option (Right to Buy)
45.15
2023-03-14
4
A
0
100000
0.00
A
2033-03-14
Common Shares
100000
100000
D
Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
This restricted stock unit award was granted on March 14, 2023 with respect to 40,000 Common Shares, with (i) one quarter of the shares vesting on March 14, 2024, (ii) one quarter of the shares vesting on March 14, 2025, (iii) one quarter of the shares vesting on March 14, 2026, and (iv) one quarter of the shares vesting on March 14, 2027.
This option was granted on March 14, 2023 with respect to 100,000 Common Shares, with 25% of the shares vesting on March 14, 2024 and the remaining shares vesting on each monthly anniversary thereafter for a period of 36 months.
/s/ Elizabeth Ryland Waldinger, attorney-in-fact
2023-03-14